^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    itraconazole

    Company:
    Generic mfg.
    Drug class:
    CYP51A1 inhibitor
    Related drugs:
    2d
    A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017) (clinicaltrials.gov)
    P1, N=14, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    prednisone • itraconazole • opevesostat (MK-5684)
    5d
    A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021) (clinicaltrials.gov)
    P1, N=44, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1 trial
    |
    itraconazole
    9d
    Itraconazole to Prevent Recurrent Barrett's Esophagus (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, University of Kansas Medical Center | Trial completion date: Jun 2026 --> Dec 2026
    Trial completion date
    |
    itraconazole
    10d
    A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants (clinicaltrials.gov)
    P1, N=30, Recruiting, BeOne Medicines | Not yet recruiting --> Recruiting
    Enrollment open
    |
    itraconazole
    11d
    A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, AbbVie
    New P1 trial
    |
    itraconazole
    11d
    A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants (clinicaltrials.gov)
    P1, N=14, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    itraconazole
    12d
    A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants (clinicaltrials.gov)
    P1, N=51, Completed, Incyte Corporation | Recruiting --> Completed
    Trial completion
    |
    itraconazole
    12d
    A Study to Learn if a Medicine Called Itraconazole Changes How the Body Processes the Study Medicine PF-08642534 in Healthy Adults. (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Pfizer | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    itraconazole
    16d
    Targeting VDAC and Autophagy in Head and Neck Oral Squamous Carcinoma: Synergy of Itraconazole and Hydroxychloroquine. (PubMed, Oral Dis)
    Taken together, these findings support itraconazole as a promising candidate for further in vivo and clinical investigation in selected oral cancers, including HNSCC and OSCC. Nevertheless, the definition of clinical treatment schedules will require additional comprehensive pharmacokinetic, toxicological, and clinical studies.
    Journal
    |
    VDAC1 (Voltage Dependent Anion Channel 1)
    |
    cisplatin • hydroxychloroquine • itraconazole
    17d
    Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions With the Antibody-Drug Conjugate Trastuzumab Deruxtecan. (PubMed, CPT Pharmacometrics Syst Pharmacol)
    The topoisomerase I inhibitor payload (DXd) released from the human epidermal growth factor receptor 2-targeted antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) is eliminated by hepatic uptake via OATP1B1/3, metabolism by CYP3A, biliary excretion via P-glycoprotein and breast cancer resistance protein, and urinary excretion. DDIs with ritonavir and itraconazole simulated by the PBPK model reproduced the clinical DDI study results, indicating that the impact of concomitant medications was not clinically meaningful. These findings suggest that this model may potentially be used for DDI evaluation of future DXd-containing ADCs, aiding in the prediction of DDIs under different scenarios and in specific populations.
    PK/PD data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • itraconazole • ritonavir
    23d
    SHR-A1811-105: Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=17, Completed, Jiangsu HengRui Medicine Co., Ltd. | N=32 --> 17 | Trial completion date: Aug 2026 --> Oct 2025 | Trial primary completion date: Jun 2025 --> Oct 2025 | Recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    trastuzumab rezetecan (SHR-A1811) • itraconazole • ritonavir
    24d
    Drug Interaction and Food Effect Study of CS0159 (clinicaltrials.gov)
    P1, N=32, Completed, Cascade Pharmaceuticals, Inc | Trial primary completion date: Feb 2027 --> Mar 2026 | Not yet recruiting --> Completed | Trial completion date: Feb 2027 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    itraconazole • rifampicin